-
Ferring Pharmaceuticals Inc. et al v. Fresenius Kabi USA, LLC et al DC CAFC
- 1:20-cv-00431
- D. Del.
- Judge: Maryellen Noreika
- Filed: 03/26/2020
- Closed: 01/30/2023
- Latest Docket Entry: 03/07/2023
- PACER
- Docket updated daily
4
Plaintiffs
2
Defendants
1
Accused
Product
8
Patents-in-Suit
1,041
Days in
Litigation
-
Ferring Pharmaceuticals Inc. et al v. Fresenius Kabi USA, LLC et al DC CAFC
- 1:20-cv-00431
- D. Del.
- Judge: Maryellen Noreika
- Filed: 03/26/2020
- Closed: 01/30/2023
- Latest Docket Entry: 03/07/2023
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 10 |
The method of claim 2, wherein the organic solvent is dimethyl formamide.
|
Valid
Entry 234 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The method of claim 1, wherein administering degarelix to the subject comprises administering an initial does of about 240 mg of degarelix; and administering a maintenance does of about 80 mg degarelix, once every approximately 28 days thereafter.
|
Valid
Entry 234 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 3 |
The method of claim 1, wherein the treated subject has a decreased likelihood of developing or experiencing an undesirable side effect during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
|
Invalid
Entry 234 |
| 13 |
The method of claim 12, wherein the maintenance dose is administered at a concentration of 20 mg/mL of degarelix.
|
Invalid
Entry 234 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The method of claim 1, wherein administering degarelix to the subject comprises administering an initial dose of about 240 mg of degarelix; and administering a maintenance dose of about 80 mg degarelix, once every approximately 28 days thereafter.
|
Valid
Entry 234 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 16 |
The method of claim 14, wherein the subject has a decreased likelihood of developing or experiencing an undesirable side effect during treatment compared to treatment with gonadotrophin releasing hormone (GnRH) agonist leuprolide.
|
Invalid
Entry 234 |
| 26 |
The method of claim 14, wherein the maintenance dose is administered at a concentration of 20 mg/mL.
|
Invalid
Entry 234 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 3 |
The method of claim 1, wherein the treatment provides a decreased likelihood of developing or experiencing an increase in arthralgia compared to the treatment with the GnRH agonist.
|
Valid
Entry 234 |
| 5 |
The method of claim 1, wherein the initial dose is 240 mg of degarelix and the maintenance dose is about 80 mg of degarelix, wherein the maintenance dose is administered once every approximately 28 days of treatment.
|
Valid
Entry 234 |
| 8 |
The method of claim 1, wherein the GnRH agonist is leuprolide.
|
Valid
Entry 234 |
| 14 |
The method of claim 1, wherein the maintenance dose of degarelix is administered at a concentration of 20 mg/m L.
|
Valid
Entry 234 |
-
Infringement
Fresenius KABI AG
- 6 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic degarelix for injection | US 10,695,398 B2 |
2
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 10,729,739 B2 |
16, 26
|
Infringement
Entry 234
|
| Generic degarelix for injection | US 10,973,870 B2 |
3, 5, 8, 14
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 8,828,938 B2 |
10
|
Infringement
Entry 234
|
| Generic degarelix for injection | US 9,415,085 B2 |
2
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 9,579,359 B2 |
3, 13
|
Infringement
Entry 234
|
Fresenius KABI USA LLC
- 6 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic degarelix for injection | US 10,695,398 B2 |
2
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 10,729,739 B2 |
16, 26
|
Infringement
Entry 234
|
| Generic degarelix for injection | US 10,973,870 B2 |
3, 5, 8, 14
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 8,828,938 B2 |
10
|
Infringement
Entry 234
|
| Generic degarelix for injection | US 9,415,085 B2 |
2
|
No infringement
Entry 234
|
| Generic degarelix for injection | US 9,579,359 B2 |
3, 13
|
Infringement
Entry 234
|
